AMG 357

AMG 357 is a small molecule antagonist of the C-C chemokine receptor type 2 (CCR2) that was developed by Amgen for the treatment of inflammatory diseases, specifically rheumatoid arthritis (RA). CCR2 is a G protein-coupled receptor that binds to monocyte chemoattractant protein-1 (MCP-1/CCL2), a key mediator in the recruitment of monocytes and macrophages to sites of inflammation. By blocking CCR2, AMG 357 was intended to reduce the infiltration of these inflammatory cells into the synovium, thereby alleviating the symptoms and progression of RA. Clinical development reached Phase 1, with studies evaluating safety, tolerability, and pharmacokinetics in healthy volunteers and female patients with RA. However, development appears to have been discontinued as the candidate no longer appears in Amgen's active pipeline.

Other names

AMG 357AMG357AMG-357